ANNA AHLBERG NEW CFO AT VITROLIFE AB (publ)

ANNA AHLBERG NEW CFO AT VITROLIFE AB (publ) Anna Ahlberg has been appointed as Head of Vitrolife's accounting and financing department and for investor relations. Anna Ahlberg has worked within the field of accounting and financing, as well as with investor relations, since 1994, first at Monark Stiga AB, a company at the time listed at the Stockholm Stock Exchange in Sweden, and then at Q-Med AB. Q-Med is a medical device company where Anna worked first as Financial Manager and then after the listing of the company in 1999 as Director of Investor Relations. Anna's last position has been as business controller at Caran, a company owned by WM-data AB, a listed company providing IT-related services. Anna will start at Vitrolife during the month of August. Gothenburg, June 22, 2004. Vitrolife AB (publ) For further information, please contact; CEO: Dr. Magnus Nilsson CFO and IR agent: Anna Ahlberg Tel: +46 31 721 80 00 Tel: +46 31 761 10 36 Mobile +46 708 22 80 61 mnilsson@vitrolife.com aahlberg@vitrolife.com Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations is focused on three geographic areas. · Europe/Middle East · The Americas · Rest of the World Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/06/22/20040622BIT00320/wkr0001.pdf

About Us

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. Vitrolife has approximately 330 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Subscribe

Documents & Links